Tuberculosis Clinical Trial
Official title:
A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects.
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study
conducted at one study center in the United States. Three (3) multiple ascending dose cohorts
are planned with twelve (12) healthy subjects (9 active and 3 placebo) in each cohort. There
will also be a dose formulation comparison cohort, enrollment of six (6) subjects is planned.
An additional multiple dose cohort of twelve (12) subjects may be enrolled.
Safety will be assessed throughout the study; serial ECGs and serial blood samples will be
collected for the safety and pharmacokinetics (PK) assessment of TBA‐354.
Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor,
in conjunction with the Principal Investigator, has determined that adequate safety,
tolerability and PK from the previous cohort has been demonstrated to permit proceeding to
the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal
Investigator, may decide to:
1. Escalate the dose as planned.
2. Evaluate an intermediate dose level prior to proceeding to the next planned dose level
if concerns arise from PK and safety that do not warrant in ceasing escalation.
3. Repeat a given dose level in a new cohort of subjects.
4. Increase the dose of the next cohort if the PK is lower than expected in the previous
cohort.
5. Add a cohort if the PK is lower than expected after a cohort and there are no safety
concerns.
6. Halt the study.
During dose escalation, at no time will the projected Cmax of any individual exceed 7.6
µg/mL, which is the highest mean value at the no-observed-adverse-effect-level from the
3-month log toxicology study TBA 354 NCLN-103. The predicted median Cmax of the final cohort
can exceed 3.2 µg/mL only if there have been no safety concerns.
Subjects in the Multiple Ascending Dose (MAD) Cohorts will be housed in the Celerion clinic
from check-in to Day 15. Subjects will return to the clinic each day from Day 16-Day 21 and
have a final one-week follow up phone interview upon completion. Subjects in the Dose
Formulation Cohort will be housed in the Clerion clinic from check-in to Day 3, visit the
clinic each day for Days 4-7, and be housed in the clinic for Days 14-16. Then subjects will
return for a daily visit for Days 17-20, and be contacted for a final one-week follow up
phone interview upon completion on Day 28.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |